EPCAM and prostate carcinoma: Some examples include (i) the AMG330 anti-CD33 BiTE to treat patients with R/R acute myeloid leukaemia (AML),13 (ii) the Pasotuxizumab (AMG 212) for treatment of patients with metastatic castration-resistant prostate cancer,14 and (iii) the Solitumomab targeting epithelial cell adhesion molecule (EpCAM) in patients with R/R advanced stage solid cancers.15